Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition

EZH2 inhibitors have gained great interest for their use as anti-cancer therapeutics. However, most research has focused on EZH2 mutant cancers and recently adverse effects of EZH2 inactivation have come to light. To determine whether colorectal cancer cells respond to EZH2 inhibition and to explore...

Descripción completa

Detalles Bibliográficos
Autores principales: Koppens, Martijn AJ, Bounova, Gergana, Cornelissen-Steijger, Paulien, de Vries, Nienke, Sansom, Owen J, Wessels, Lodewyk FA, van Lohuizen, Maarten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342517/
https://www.ncbi.nlm.nih.gov/pubmed/27634879
http://dx.doi.org/10.18632/oncotarget.12002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342517/
https://www.ncbi.nlm.nih.gov/pubmed/27634879
http://dx.doi.org/10.18632/oncotarget.12002

Ejemplares similares